English
English Indonesia Türkçe Deutsch Español Português Pусский Français Italiano Nederlands Polski العربية ไทย Tiếng Việt 繁體中文 简体中文 日本語 한국어

#immunotherapy search results

diegoadiazg's profile picture. Medical Oncologist • Thoracic Oncology @incanMX alum | #CánCare • Hosp. Ángeles del Carmen | Views my own
Diego A. Díaz-García
@diegoadiazg
Apr 3

🫁 CHIO3: Chemo + Durvalumab in N2 NSCLC. N2 clearance: 73.3% pCR: 30% R0: 93.3% 18-mo EFS: 60.6% Feasible, low toxicity, strong nodal downstaging in N2+ disease. 📖 Lung Cancer DOI 👉🏻 doi.org/10.1016/j.lung… #CánCare #NSCLC #Immunotherapy #lcsm

diegoadiazg's tweet image. 🫁 CHIO3: Chemo + Durvalumab in N2 NSCLC. N2 clearance: 73.3% pCR: 30% R0: 93.3% 18-mo EFS: 60.6% Feasible, low toxicity, strong nodal downstaging in N2+ disease. 📖 Lung Cancer DOI 👉🏻 doi.org/10.1016/j.lung… #CánCare #NSCLC #Immunotherapy #lcsm
diegoadiazg's tweet image. 🫁 CHIO3: Chemo + Durvalumab in N2 NSCLC. N2 clearance: 73.3% pCR: 30% R0: 93.3% 18-mo EFS: 60.6% Feasible, low toxicity, strong nodal downstaging in N2+ disease. 📖 Lung Cancer DOI 👉🏻 doi.org/10.1016/j.lung… #CánCare #NSCLC #Immunotherapy #lcsm
diegoadiazg's tweet image. 🫁 CHIO3: Chemo + Durvalumab in N2 NSCLC. N2 clearance: 73.3% pCR: 30% R0: 93.3% 18-mo EFS: 60.6% Feasible, low toxicity, strong nodal downstaging in N2+ disease. 📖 Lung Cancer DOI 👉🏻 doi.org/10.1016/j.lung… #CánCare #NSCLC #Immunotherapy #lcsm
diegoadiazg's tweet image. 🫁 CHIO3: Chemo + Durvalumab in N2 NSCLC. N2 clearance: 73.3% pCR: 30% R0: 93.3% 18-mo EFS: 60.6% Feasible, low toxicity, strong nodal downstaging in N2+ disease. 📖 Lung Cancer DOI 👉🏻 doi.org/10.1016/j.lung… #CánCare #NSCLC #Immunotherapy #lcsm
1
3
13
7
925
DSSImagetech's profile picture. biotechnology equipments & consumables, molecular diagnostics products, medical devices supplier
DSS Imagetech Pvt Ltd
 @DSSImagetech
7 h

Seminar on Agilent Dako's PD-L1 Join us at Anderson Diagnostics and Labs, Chennai for an insightful session on the evolving role of PD-L1 testing in immunotherapy and precision oncology. Registration Link: docs.google.com/forms/d/e/1FAI… #PDL1 #CompanionDiagnostics #Immunotherapy

DSSImagetech's tweet image. Seminar on Agilent Dako's PD-L1 Join us at Anderson Diagnostics and Labs, Chennai for an insightful session on the evolving role of PD-L1 testing in immunotherapy and precision oncology. Registration Link: docs.google.com/forms/d/e/1FAI… #PDL1 #CompanionDiagnostics #Immunotherapy
0
0
0
0
6
ChandrakanthMv's profile picture. Medical Oncologist (Breast • GU • GI) Simplifying Oncology for DoctorsI Building MV Onco I Head Academics | Narayana Health Kolkata
MV Chandrakanth
@ChandrakanthMv
Mar 29

Phase 3 (PRESERVE-003): Gotistobart vs Docetaxel Post PD-(L)1 resistant sqNSCLC Early overlap → late separation (~6 months) HR 0.46 | Durable OS benefit 👉 Classic immunotherapy effect #MVOnco #NSCLC #Immunotherapy #LungCancer

ChandrakanthMv's tweet image. Phase 3 (PRESERVE-003): Gotistobart vs Docetaxel Post PD-(L)1 resistant sqNSCLC Early overlap → late separation (~6 months) HR 0.46 | Durable OS benefit 👉 Classic immunotherapy effect #MVOnco #NSCLC #Immunotherapy #LungCancer
3
7
33
14
3K
ThomasVitins's profile picture. Passionate about Music, History, Politics, Science, Art, Paintings | Swiss🇨🇭| Solidarity 🇵🇸
Thomas Vitins
 @ThomasVitins
Apr 14

'It's incredible, like science fiction': How a new wave of #immunotherapy is eliminating cancers After 100 years of development, treatments that bolster the body's immune system to fight #cancer are coming of age – and saving patients' By Jamie Ducharme bbc.com/future/article…

ThomasVitins's tweet card. After nearly 100 years of development, treatments that bolster the body's immune system to fight cancer are coming of age – and saving patients' lives.
'It's incredible, like science fiction': How a new wave of immunotherapy is eliminating cancers
Source: bbc.com
0
1
1
0
12
JAMA_current's profile picture. JAMA is an international peer-reviewed general medical journal published weekly online and in print, and a member of the @JAMANetwork family of journals.
JAMA
@JAMA_current
Mar 15

Allergy to peanuts affects approximately 2% of individuals in the US. 💡 This JAMA Insights discusses #PeanutAllergy, including diagnosis, introduction of peanuts to infant diet, and #immunotherapy options. ja.ma/4bnHMCf

JAMA_current's tweet image. Allergy to peanuts affects approximately 2% of individuals in the US. 💡 This JAMA Insights discusses #PeanutAllergy, including diagnosis, introduction of peanuts to infant diet, and #immunotherapy options. ja.ma/4bnHMCf
1
9
27
7
5K
OscarTahuahua's profile picture. Medical oncologist @incanMX | Thoracic oncology | What’s changing in cancer care — and why it matters | @OncoAlert 🌎
Oscar Tahuahua
@OscarTahuahua
Mar 29

One hidden tumor population can decide if #immunotherapy works or fails In CRC A single clonal neoantigen → ~70% durable response vs ~10% without it dMMR tumors respond but still fail due to heterogeneity ICI clears immunogenic clones → low-immunogenic subclones survive,

OscarTahuahua's tweet image. One hidden tumor population can decide if #immunotherapy works or fails In CRC A single clonal neoantigen → ~70% durable response vs ~10% without it dMMR tumors respond but still fail due to heterogeneity ICI clears immunogenic clones → low-immunogenic subclones survive,
3
31
111
73
12K
cdrjournal's profile picture. Impact Factor 2024: 5.2 - Q1 (ONCOLOGY); CiteScore 2024: 8.3 - Q1 Pharmacology(medical). Indexed in PubMed Central(PMC), ESCI and Scopus #Cancer #DrugResistance
Cancer Drug Resistance
 @cdrjournal
2 h

👉The review provides a mechanistic roadmap for using #nanomaterial-based strategies as pathway-matched, programmable interventions to overcome primary #resistance to PD-1/PD-L1 inhibitors. PD-1/PD-L1, #immunotherapy, immune resistance, nanomaterials 👀oaepublish.com/articles/cdr.2…

cdrjournal's tweet image. 👉The review provides a mechanistic roadmap for using #nanomaterial-based strategies as pathway-matched, programmable interventions to overcome primary #resistance to PD-1/PD-L1 inhibitors. PD-1/PD-L1, #immunotherapy, immune resistance, nanomaterials 👀oaepublish.com/articles/cdr.2…
0
0
0
0
8
cGxPWire's profile picture. CGXP Wire is built with a simple purpose — to share meaningful content that truly matters to people. In a world full of noise, we focus on creating value.
cGxP Wire
 @cGxPWire
2 h

🚀 Enara Bio showcases ENA101 cancer immunotherapy at AACR Advancing next-gen immune-targeted oncology therapies. 👉 cgxpwire.com/biopharma/enar… #Immunotherapy #Oncology #AACR

cGxPWire's tweet image. 🚀 Enara Bio showcases ENA101 cancer immunotherapy at AACR Advancing next-gen immune-targeted oncology therapies. 👉 cgxpwire.com/biopharma/enar… #Immunotherapy #Oncology #AACR
0
0
0
0
8
ChandrakanthMv's profile picture. Medical Oncologist (Breast • GU • GI) Simplifying Oncology for DoctorsI Building MV Onco I Head Academics | Narayana Health Kolkata
MV Chandrakanth
@ChandrakanthMv
Mar 31

“Clear cell ovarian cancer behaves differently. Not chemo-driven… but immune responsive. Phase 2 MoST-CIRCUIT shows Nivo+Ipi with 54% ORR and durable responses. Time to rethink biology. 🔥 #MVOnco #GynOnc #Immunotherapy”

ChandrakanthMv's tweet image. “Clear cell ovarian cancer behaves differently. Not chemo-driven… but immune responsive. Phase 2 MoST-CIRCUIT shows Nivo+Ipi with 54% ORR and durable responses. Time to rethink biology. 🔥 #MVOnco #GynOnc #Immunotherapy”
0
5
13
5
879
myESMO's profile picture. The European Society for Medical Oncology (ESMO) is a reference organisation for cancer education and information, supporting the oncology community’s work.
ESMO - Eur. Oncology
@myESMO
Mar 13

#ESMORareCancers26: Adding first-line #immunotherapy to methotrexate improved response in patients with low-risk gestational trophoblastic neoplasia (#GTN) but must be balanced w/ safety & fertility considerations. ➡️Check out the #ESMODailyReporter: ow.ly/1gXW50YsKII

myESMO's tweet image. #ESMORareCancers26: Adding first-line #immunotherapy to methotrexate improved response in patients with low-risk gestational trophoblastic neoplasia (#GTN) but must be balanced w/ safety & fertility considerations. ➡️Check out the #ESMODailyReporter: ow.ly/1gXW50YsKII
0
5
10
2
1K
EssenBiotech's profile picture. Leaders in personalized cellular therapies. 🧬 We specialize in CAR-T, MSC, and NK cell treatments. Offering hope and innovation to patients worldwide. 🌍
Essen BioTech
 @EssenBiotech
Apr 16

Essen Biotech trial radar: NCT06532812 (BAH249) — TIL + immunotherapy for refractory breast cancer. Talk to your oncology team. #Immunotherapy #oncology #hematology #CancerResearch #EssenBiotech #ClinicalTrials #Cancer #Genetherapy #CancerTrials #CART #TIL #NK #Breastcancer

EssenBiotech's tweet image. Essen Biotech trial radar: NCT06532812 (BAH249) — TIL + immunotherapy for refractory breast cancer. Talk to your oncology team. #Immunotherapy #oncology #hematology #CancerResearch #EssenBiotech #ClinicalTrials #Cancer #Genetherapy #CancerTrials #CART #TIL #NK #Breastcancer
0
0
0
0
13
GRUrology's profile picture. We share urology treatment updates by experts in the field. Join the community: https://t.co/Ode9zqjG8O
Grand Rounds Urology
@GRUrology
Apr 2

.@DrTylerStewart, MD, @UCSD, provides a clear rationale for integrating #immunotherapy into the perioperative management of muscle-invasive bladder cancer. #BladderCancer #Urology #MIBC

0
2
8
4
2K
GENbio's profile picture. Serving the biotech industry since 1981. EIC @johnsterling4; publisher @liebertpub Subscribe to GEN: https://t.co/KzqMccOt9Q
Genetic Engineering & Biotechnology News
 @GENbio
Mar 25

Immunotherapy for Solid Tumors Enhanced by Metabolite-Sensing Receptors A new approach engineers immune cells to recognize byproducts of cancer cells to trigger migration toward the tumor @LivnatJerby @Stanford #immunotherapy #cancercells #tumors #GPCR hubs.li/Q048gZQd0

GENbio's tweet card. A new approach engineers immune cells to recognize byproducts of cancer cells to trigger migration toward the tumor.  
Immunotherapy for Solid Tumors Enhanced by Metabolite-Sensing Receptors
Source: genengnews.com
0
2
6
0
492
PatrickHwuMD's profile picture. Moffitt Cancer Center President and CEO, @MoffittNews. Tumor immunologist. Inspired leader. Girl dad. #DocsWhoRock. Driven to save more lives from #cancer.
Dr. Patrick Hwu
@PatrickHwuMD
Apr 11

🧬 #ScienceSaturday ❓ What if we could block cancer’s ability to survive in low-oxygen environments and make #immunotherapy more effective? ➡️ In a new study published in the Journal of Experimental Medicine (@JExpMed), researchers developed dual inhibitors targeting HIF-1 and

PatrickHwuMD's tweet image. 🧬 #ScienceSaturday ❓ What if we could block cancer’s ability to survive in low-oxygen environments and make #immunotherapy more effective? ➡️ In a new study published in the Journal of Experimental Medicine (@JExpMed), researchers developed dual inhibitors targeting HIF-1 and
3
20
69
23
5K
JochenReiser's profile picture. President of UTMB and CEO, UTMB Health System at the University of Texas @utmbhealth @UTMBPresident
Jochen Reiser MD PhD
@JochenReiser
Apr 10

Great new paper in Cell 😎 What if we’ve been targeting the wrong thing in solid tumors? uPAR CAR T cells don’t just attack cancer cells but instead they dismantle the entire tumor ecosystem. Tumor + stroma + senescence. A potential paradigm shift. #uPAR #Immunotherapy 👇👇 A

cell.com

A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy

Synergizing with senescence-inducing therapies, uPAR CAR T cells eradicate primary and metastatic solid tumors with minimal myelodepletion by targeting both tumor cells and the stroma in preclinical...

Source: cell.com
1
1
5
0
374
ahighelevation's profile picture. I work with Independent Research Analysts, Micro Cap Companies and Investors #biotech #smallcap https://t.co/ikx9CfTU5e…
Giles
 @ahighelevation
Apr 14

$IMNN: Enrollment Ahead of Schedule in P3 Ovarian Cancer Trial #biopharma #immunotherapy #vaccines #DNA buff.ly/254Tg6g

ahighelevation's tweet image. $IMNN: Enrollment Ahead of Schedule in P3 Ovarian Cancer Trial #biopharma #immunotherapy #vaccines #DNA buff.ly/254Tg6g
0
1
0
0
44
sigtrans_sttt's profile picture. Signal Transduction and Targeted Therapy (STTT) | A Nature Portfolio Journal | Impact Factor 52.7 | CiteScore: 58.6 | Peer-reviewed | Open Access |
Signal Transduction and Targeted Therapy (STTT)
@sigtrans_sttt
now

SRSF1 inhibition enhances #Cancer #Immunotherapy by restoring CD8⁺ T-cell function and disrupting tumor metabolism, with TN2008 showing improved #Antitumor responses in preclinical models. #STTT #OpenAccess: doi.org/10.1038/s41392…

sigtrans_sttt's tweet image. SRSF1 inhibition enhances #Cancer #Immunotherapy by restoring CD8⁺ T-cell function and disrupting tumor metabolism, with TN2008 showing improved #Antitumor responses in preclinical models. #STTT #OpenAccess: doi.org/10.1038/s41392…
0
0
0
0
0
IET_online's profile picture. Monitoring, Analysis, Testing & Solutions from the publishers of International Environmental Technology (IET). #Environment, #Pollution,#Water,#Air related news
Envirotech
@IET_online
1 h

The latest Labmate UK & Ireland eBulletin explores how emerging evidence continues to refine clinical insight & #laboratory capability across #cardiology, #immunotherapy, #neurology & analytical science👉 ilmt.co/TL/O8Rp Subscription is free👉 ilmt.co/TL/jzlL

0
0
0
0
6
healthtechworld's profile picture. The platform for everyone with a professional interest in health technology.
Health Tech World
@healthtechworld
2 h

Bowel cancer patients stayed cancer-free for nearly three years after immunotherapy before surgery in a clinical trial. 🔗 Full story: buff.ly/uuTK3L0 #BowelCancer #CancerResearch #Immunotherapy #ClinicalTrial #UKHealth

healthtechworld's tweet image. Bowel cancer patients stayed cancer-free for nearly three years after immunotherapy before surgery in a clinical trial. 🔗 Full story: buff.ly/uuTK3L0 #BowelCancer #CancerResearch #Immunotherapy #ClinicalTrial #UKHealth
0
1
1
0
6
cdrjournal's profile picture. Impact Factor 2024: 5.2 - Q1 (ONCOLOGY); CiteScore 2024: 8.3 - Q1 Pharmacology(medical). Indexed in PubMed Central(PMC), ESCI and Scopus #Cancer #DrugResistance
Cancer Drug Resistance
 @cdrjournal
2 h

👉The review provides a mechanistic roadmap for using #nanomaterial-based strategies as pathway-matched, programmable interventions to overcome primary #resistance to PD-1/PD-L1 inhibitors. PD-1/PD-L1, #immunotherapy, immune resistance, nanomaterials 👀oaepublish.com/articles/cdr.2…

cdrjournal's tweet image. 👉The review provides a mechanistic roadmap for using #nanomaterial-based strategies as pathway-matched, programmable interventions to overcome primary #resistance to PD-1/PD-L1 inhibitors. PD-1/PD-L1, #immunotherapy, immune resistance, nanomaterials 👀oaepublish.com/articles/cdr.2…
0
0
0
0
8
cGxPWire's profile picture. CGXP Wire is built with a simple purpose — to share meaningful content that truly matters to people. In a world full of noise, we focus on creating value.
cGxP Wire
 @cGxPWire
2 h

🚀 Enara Bio showcases ENA101 cancer immunotherapy at AACR Advancing next-gen immune-targeted oncology therapies. 👉 cgxpwire.com/biopharma/enar… #Immunotherapy #Oncology #AACR

cGxPWire's tweet image. 🚀 Enara Bio showcases ENA101 cancer immunotherapy at AACR Advancing next-gen immune-targeted oncology therapies. 👉 cgxpwire.com/biopharma/enar… #Immunotherapy #Oncology #AACR
0
0
0
0
8
IJMS_MDPI's profile picture. International Journal of Molecular Sciences (ISSN 1422-0067;IF: 4.9) is an OA journal providing an advanced forum for chemistry, molecular physics and biology.
IJMS MDPI
 @IJMS_MDPI
3 h

🧬 We're glad to share the #MDPI Workshop "Cutting-Edge Advances in Cancer Immunology & Immunotherapy" 📅 8 May 2026 📍University of Southern California (USC), USA Meet our prestigious speakers🌟 🔗Free Register: forms.office.com/e/XZweVunq25 #CancerResearch #Immunotherapy

IJMS_MDPI's tweet image. 🧬 We're glad to share the #MDPI Workshop "Cutting-Edge Advances in Cancer Immunology & Immunotherapy" 📅 8 May 2026 📍University of Southern California (USC), USA Meet our prestigious speakers🌟 🔗Free Register: forms.office.com/e/XZweVunq25 #CancerResearch #Immunotherapy
0
0
0
0
18
EssenBiotech's profile picture. Leaders in personalized cellular therapies. 🧬 We specialize in CAR-T, MSC, and NK cell treatments. Offering hope and innovation to patients worldwide. 🌍
Essen BioTech
 @EssenBiotech
5 h

Sequential targeting (CD33 then CD123) is being studied to broaden AML coverage. See NCT06420063 (BAH244). #Immunotherapy #oncology #hematology #CancerResearch #EssenBiotech #ClinicalTrials #Cancer #Sicklecell #Genetherapy #CancerTrials #Patientcare #Health #CART #TIL #NK

0
0
0
0
2
drvasu_onco's profile picture. Consultant Medical Oncologist & BMT Physician 🩺 Renova-Century Hospital, Hyderabad 📞 +91 9801992974
Dr Vasu Babu
 @drvasu_onco
5 h

CAR T cell therapy uses immune cells to target resistant cancers offering personalized advanced treatment and hope #CARTTherapy #Immunotherapy #CancerCare #Oncology #AdvancedTreatment consult specialist today #DrGVasuBabu #OncologistIndia #MedicalOncologist #HematoOncologist

drvasu_onco's tweet image. CAR T cell therapy uses immune cells to target resistant cancers offering personalized advanced treatment and hope #CARTTherapy #Immunotherapy #CancerCare #Oncology #AdvancedTreatment consult specialist today #DrGVasuBabu #OncologistIndia #MedicalOncologist #HematoOncologist
0
0
0
0
1
DSSImagetech's profile picture. biotechnology equipments & consumables, molecular diagnostics products, medical devices supplier
DSS Imagetech Pvt Ltd
 @DSSImagetech
7 h

Seminar on Agilent Dako's PD-L1 Join us at Anderson Diagnostics and Labs, Chennai for an insightful session on the evolving role of PD-L1 testing in immunotherapy and precision oncology. Registration Link: docs.google.com/forms/d/e/1FAI… #PDL1 #CompanionDiagnostics #Immunotherapy

DSSImagetech's tweet image. Seminar on Agilent Dako's PD-L1 Join us at Anderson Diagnostics and Labs, Chennai for an insightful session on the evolving role of PD-L1 testing in immunotherapy and precision oncology. Registration Link: docs.google.com/forms/d/e/1FAI… #PDL1 #CompanionDiagnostics #Immunotherapy
0
0
0
0
6
ClinOncNews's profile picture. An independent source of unbiased, accurate, reliable news and in-depth expert analysis on issues oncologists and hematologist/oncologists care about most.
ClinicalOncologyNews
@ClinOncNews
10 h

📊 Study finds increased adenoma risk after ICI-related colitis, with a sharp rise around ~7 months. What does this mean for surveillance? clinicaloncology.com/a/5zcBAA/t #Oncology #Immunotherapy #GI

0
0
0
0
31
HepatomaRes's profile picture. A gold open-access journal, indexed in ESCI 、WOS, and Scopus, 2024 IF: 1.2. #livercancer #HCC #CCA #Hepatitis #liverdisease #livertwitter #MedEd #HCCtwitter
Hepatoma Research
 @HepatomaRes
11 h

💬 What matters most before starting IO + TACE in HCC? 🧬 Immune profiling ⚠️ Liver function 📊 Toxicity prediction 🎯 Tumor response potential Vote & discuss 👇 #HCC #Immunotherapy @ozdogan_md @AustinBourgeois @pashtoonkasi @SuyogCancer @DrAngelaLamarca @jryckman3 @NiuSanford

HepatomaRes's profile picture. A gold open-access journal, indexed in ESCI 、WOS, and Scopus, 2024 IF: 1.2. #livercancer #HCC #CCA #Hepatitis #liverdisease #livertwitter #MedEd #HCCtwitter
Hepatoma Research
 @HepatomaRes
11 h

🛡️ Predicting Severe irAEs in HCC After TACE + Immunotherapy Can baseline immune profiling identify patients at risk for severe immune-related adverse events? 🔗f.oaes.cc/xmlpdf/publish… #HCC #Immunotherapy #TACE #PrecisionMedicine

HepatomaRes's tweet image. 🛡️ Predicting Severe irAEs in HCC After TACE + Immunotherapy Can baseline immune profiling identify patients at risk for severe immune-related adverse events? 🔗f.oaes.cc/xmlpdf/publish… #HCC #Immunotherapy #TACE #PrecisionMedicine
HepatomaRes's tweet image. 🛡️ Predicting Severe irAEs in HCC After TACE + Immunotherapy Can baseline immune profiling identify patients at risk for severe immune-related adverse events? 🔗f.oaes.cc/xmlpdf/publish… #HCC #Immunotherapy #TACE #PrecisionMedicine
HepatomaRes's tweet image. 🛡️ Predicting Severe irAEs in HCC After TACE + Immunotherapy Can baseline immune profiling identify patients at risk for severe immune-related adverse events? 🔗f.oaes.cc/xmlpdf/publish… #HCC #Immunotherapy #TACE #PrecisionMedicine
HepatomaRes's tweet image. 🛡️ Predicting Severe irAEs in HCC After TACE + Immunotherapy Can baseline immune profiling identify patients at risk for severe immune-related adverse events? 🔗f.oaes.cc/xmlpdf/publish… #HCC #Immunotherapy #TACE #PrecisionMedicine
0
0
1
0
687
0
1
3
0
278
HepatomaRes's profile picture. A gold open-access journal, indexed in ESCI 、WOS, and Scopus, 2024 IF: 1.2. #livercancer #HCC #CCA #Hepatitis #liverdisease #livertwitter #MedEd #HCCtwitter
Hepatoma Research
 @HepatomaRes
11 h

🛡️ Predicting Severe irAEs in HCC After TACE + Immunotherapy Can baseline immune profiling identify patients at risk for severe immune-related adverse events? 🔗f.oaes.cc/xmlpdf/publish… #HCC #Immunotherapy #TACE #PrecisionMedicine

HepatomaRes's tweet image. 🛡️ Predicting Severe irAEs in HCC After TACE + Immunotherapy Can baseline immune profiling identify patients at risk for severe immune-related adverse events? 🔗f.oaes.cc/xmlpdf/publish… #HCC #Immunotherapy #TACE #PrecisionMedicine
HepatomaRes's tweet image. 🛡️ Predicting Severe irAEs in HCC After TACE + Immunotherapy Can baseline immune profiling identify patients at risk for severe immune-related adverse events? 🔗f.oaes.cc/xmlpdf/publish… #HCC #Immunotherapy #TACE #PrecisionMedicine
HepatomaRes's tweet image. 🛡️ Predicting Severe irAEs in HCC After TACE + Immunotherapy Can baseline immune profiling identify patients at risk for severe immune-related adverse events? 🔗f.oaes.cc/xmlpdf/publish… #HCC #Immunotherapy #TACE #PrecisionMedicine
HepatomaRes's tweet image. 🛡️ Predicting Severe irAEs in HCC After TACE + Immunotherapy Can baseline immune profiling identify patients at risk for severe immune-related adverse events? 🔗f.oaes.cc/xmlpdf/publish… #HCC #Immunotherapy #TACE #PrecisionMedicine
0
0
1
0
687
iesAsia's profile picture. Sharing wonderful research discoveries from global researchers in plain language, graphics, & animated videos for maximum impact Japanese content: @ies_JP
ies Research
 @iesAsia
12 h

CD24a acting as a "don't attack me" badge...... What happens if CD24a is removed? (0:38-0:45) #CD24a #ImmuneEvasion #Immunotherapy #Macrophages Learn more: buff.ly/NQdVcoR

iesAsia's tweet image. CD24a acting as a "don't attack me" badge...... What happens if CD24a is removed? (0:38-0:45) #CD24a #ImmuneEvasion #Immunotherapy #Macrophages Learn more: buff.ly/NQdVcoR
0
0
0
0
1
sciqst's profile picture. It’s pronounced “Sci-Quest.” 😉 Precise references in medicine. https://t.co/gB5L99FK55 ByronInsight AG, Zurich, Switzerland
Raffaele Di Giacomo, PhD
@sciqst
15 h

The optimization of CAR T-cell therapy is crucial for enhancing patient outcomes, particularly in cancer treatments. I'm curious, are the guidelines addressing both efficacy and safety aspects? How do they propose managing the long-term side effects that may arise? #ImmunoTherapy

0
0
0
0
8
HemOncToday's profile picture. The content you need, when you need it.
HemOnc Today
 @HemOncToday
19 h

👀 A deep learning platform may help predict how people with advanced #LungCancer will respond to #immunotherapy. Healio spoke with Dr. Rukhmini Bandyopadhyay, PhD, @UTMDAnderson about a biology-guided #AI model presented at #AACR26 @AACR 👇 vist.ly/4z5mg

HemOncToday's tweet card. A deep learning platform may help predict how people with advanced lung cancer will respond to immunotherapy, according to study results.Patients determined by a biology-guided AI model to be at high...
‘Biology-informed’ AI model may predict immunotherapy response in lung cancer
Source: healio.com
0
2
4
1
90
SU2Cscience's profile picture. SU2C's research programs prioritize the most promising new treatments for cancer. Follow us for updates on our research + funding. Also follow @SU2C for more.
SU2Cscience
@SU2Cscience
19 h

Building foundation models of the tumor genome with @TreyIdeker from @UCSDHealth at @AACR AM 2026. Dr. Ideker utilized #ProjectGENIE data to predict tumor evolution and to predict responses to #immunotherapy and chemotherapy. #AACR26 #SU2C

SU2Cscience's tweet image. Building foundation models of the tumor genome with @TreyIdeker from @UCSDHealth at @AACR AM 2026. Dr. Ideker utilized #ProjectGENIE data to predict tumor evolution and to predict responses to #immunotherapy and chemotherapy. #AACR26 #SU2C
SU2Cscience's tweet image. Building foundation models of the tumor genome with @TreyIdeker from @UCSDHealth at @AACR AM 2026. Dr. Ideker utilized #ProjectGENIE data to predict tumor evolution and to predict responses to #immunotherapy and chemotherapy. #AACR26 #SU2C
0
0
5
2
408
PatrickHwuMD's profile picture. Moffitt Cancer Center President and CEO, @MoffittNews. Tumor immunologist. Inspired leader. Girl dad. #DocsWhoRock. Driven to save more lives from #cancer.
Dr. Patrick Hwu
@PatrickHwuMD
20 h

At @AACR, excited to see how AI is shaping the future of cancer care. Nice work from Rukhmini Bandyopadhyay (@UTMDAnderson) on a deep learning pathomics platform to help predict #immunotherapy response in lung cancer. #AACR26 Read more at aacr.org/about-the-aacr…

PatrickHwuMD's tweet image. At @AACR, excited to see how AI is shaping the future of cancer care. Nice work from Rukhmini Bandyopadhyay (@UTMDAnderson) on a deep learning pathomics platform to help predict #immunotherapy response in lung cancer. #AACR26 Read more at aacr.org/about-the-aacr…
PatrickHwuMD's tweet image. At @AACR, excited to see how AI is shaping the future of cancer care. Nice work from Rukhmini Bandyopadhyay (@UTMDAnderson) on a deep learning pathomics platform to help predict #immunotherapy response in lung cancer. #AACR26 Read more at aacr.org/about-the-aacr…
1
4
5
2
608
ahighelevation's profile picture. I work with Independent Research Analysts, Micro Cap Companies and Investors #biotech #smallcap https://t.co/ikx9CfTU5e…
Giles
 @ahighelevation
20 h

$IMNN: Final Data from Phase 2 Ovarian Cancer Trial Shows Improvement in Survival of Greater Than One Year #biopharma #immunotherapy #vaccines #DNA buff.ly/05CmgkP

ahighelevation's tweet image. $IMNN: Final Data from Phase 2 Ovarian Cancer Trial Shows Improvement in Survival of Greater Than One Year #biopharma #immunotherapy #vaccines #DNA buff.ly/05CmgkP
0
0
0
0
15
AkiLeach's profile picture.
Aki Leach
 @AkiLeach
21 h

A pancreatic cancer vaccine acts as immunotherapy, targeting and eliminating residual cancer cells post-treatment. It's a crucial step in the fight against this disease. #CancerResearch #Immunotherapy

0
0
0
0
19
ChimeraResearch's profile picture. Providing independent & actionable investment & trading ideas backed by fundamental research & analysis in biotech & pharmaceuticals
Joe - ChimeraResearchGroup
 @ChimeraResearch
21 h

$MDNAF $MDNA.to ✅ First-in-human study targeted for 2026 ✅ IND submission expected H2 2026 Preparing for clinical entry! #Immunotherapy #ClinicalTrials #MDNA113 #Cancer

0
1
11
0
364
sitcancer's profile picture. Society for Immunotherapy of Cancer (SITC) - Dedicated to improving cancer patient outcomes by advancing the field of tumor immunology and cancer immunotherapy.

Society for Immunotherapy of Cancer

@sitcancer
parkerici's profile picture. Our mission is to accelerate the development of breakthrough immune therapies to turn all cancers into curable diseases.

Parker Institute for Cancer Immunotherapy

@parkerici
jitcancer's profile picture. The official journal of @SITCancer, covering all aspects of tumor immunology and cancer immunotherapy. #JITC Editor-in-Chief: Michael T. Lotze, MD

Journal for ImmunoTherapy of Cancer

@jitcancer
C_IMT's profile picture. The Association for Cancer Immunotherapy CIMT is a member-based information and education platform promoting the development of cancer immunotherapies.

Cancer Immunotherapy

@C_IMT
ImmunologyUoB's profile picture. News and updates from the Department of Immunology and Immunotherapy at @unibirmingham. College of Medicine and Health, @unibirm_CMH.

Immunology and Immunotherapy

@ImmunologyUoB
BioCanRx's profile picture. A Network of Centres of Excellence uniquely positioned to help Canada & the world accelerate the development of effective #cancer #immunotherapy treatments

BioCanRx - Canada's Immunotherapy Network

@BioCanRx
CIIC_UoB's profile picture. Cancer Immunology and Immunotherapy Centre (CIIC), a collaborative grouping of academic and clinical research groups based at the University of Birmingham, UK

Cancer Immunology and Immunotherapy Centre

@CIIC_UoB
VIU_kfmrc's profile picture. Vaccines & Immunotherapy unit | @kfmrc_official | @kauweb | Since Jan 2019 | Supervisor: @Anwar_Hashem | 📧:kfmrc_viu@kau.edu.sa

Vaccines & Immunotherapy Unit

@VIU_kfmrc
BeatCancertoday's profile picture. Offering resources to Cancer fighters around the world... You too can Beat Cancer

Immunotherapy Institute Tijuana

@BeatCancertoday
IMTadvances's profile picture. #OpenAccess journal covering the translational pipeline for #immunotherapy 🎯Included in WoS, PubMed & Scopus Official @britsocimm journal | EiC: Prof @tim_tje

Immunotherapy Advances Journal

@IMTadvances
PICIatMSK's profile picture. The @parkerici group at @MSKCancerCenter works to accelerate the development of breakthrough immune therapies capable of turning cancer into a curable disease.

MSKCC | Parker Institute for Cancer Immunotherapy

@PICIatMSK
LabWalz's profile picture. Advancing peptide-based vaccines for cancer & infectious disease | Translational immunopeptidome studies | T-cell immunology & immunotherapy | @CoE_iFIT member

Peptide-based Immunotherapy

@LabWalz
Immuno_Therapy's profile picture. Latest news, research breakthrough and business development in Cancer Immunotherapy

Cancer Immunotherapy

@Immuno_Therapy
ImmunotherapyFd's profile picture. A non-profit with a mission to treat, prevent, and ultimately cure HPV-driven cancer. We support immunotherapy research at @UCSDHealth's MCC & @ljiresearch.

Immunotherapy Foundation

@ImmunotherapyFd
WilliamKDecker's profile picture. Professor of Immunology, Baylor College of Medicine

Cancer Immunotherapy

@WilliamKDecker
LMU_Immutherapy's profile picture. We develop cellular- and antibody-based immunotherapies for malignant neoplasia, with a special focus on acute leukemia and B-cell lymphoma.

LMU Munich Immunotherapy in Hematology

@LMU_Immutherapy
FundImmuno's profile picture. Patient-led campaign to ensure vital cancer immunotherapy treatments are funded by all Irish health insurance providers.

Fund Immunotherapy Ireland

@FundImmuno
TheImmunoCNS's profile picture. The Immunotherapy ANPs at Somerset NHS Foundation Trust @MusgrovePark . Views our own unless otherwise stated.

The Immunotherapy CNS 💙

@TheImmunoCNS
immunoca's profile picture. Official Handle Of Immunotherapy Nigeria limited. Distributors of IMMUNOCAL in Nigeria

Immunotherapy Nig. Ltd

@immunoca
JCITnews's profile picture. K.G. Jebsen Centre for Cancer Immunotherapy aims to develop new strategies for Immunotherapy against Cancer

K.G. Jebsen Centre for Cancer Immunotherapy

@JCITnews
Immunotx_papers's profile picture. Searching #PubMed for new publications researching cancer immunotherapy. #Immunotherapy #CancerResearch

ImmunotherapyPapers

@Immunotx_papers
CCIConsortium's profile picture. We provide leadership to the immunotherapy community, promote innovation, and foster multi-disciplinary interaction in this rapidly evolving field.

Canadian Cancer Immunotherapy Consortium

@CCIConsortium
CancerImmunothe's profile picture. It is our hope that you will gain information which you can use, in the integrative diagnostic and treatment options available for you or your loved one.

Cancer Immunotherapy

@CancerImmunothe
CoE_PRIMA's profile picture. Precision Immunotherapy Alliance

Precision Immunotherapy Alliance

@CoE_PRIMA
TAVaccinesImm's profile picture. A @SAGE_Publishing gold open access journal | Publishing high-quality articles in the fields of vaccinology and immunotherapy | PubMed indexed | #TAVaccinesImm

Therapeutic Advances in Vaccines and Immunotherapy

@TAVaccinesImm
pirl_unc's profile picture. Multi-PI lab at UNC Chapel Hill working on novel cancer immunotherapies targeting mutant antigens. Tweets by @iskander & @benjamingvincen

Personalized Immunotherapy Research Lab

@pirl_unc
PeterMacCoE's profile picture. The Peter Mac's CoE in Cellular Immunotherapy mission is to discover, develop and deliver breakthroughs in CAR-T & other cell immunotherapies to treat cancer

Peter Mac CoE in Cellular Immunotherapy

@PeterMacCoE
ImmunotherapyC's profile picture.

Immunotherapy and Cancer Journal Club

@ImmunotherapyC
ITOCconference's profile picture. March 12 - 14, 2026

12th Immunotherapy of Cancer Conference

@ITOCconference
immunotherapy's profile picture.

Cancer Immunotherapy

@immunotherapy
CareFhu's profile picture. FHU CARE #Cancer #Autoimmunity #Immunotherapy Our Partners : • AP-HP • Inserm • Université Paris Saclay • Gustave Roussy • CNRS • CEA • Fondation Arthritis

FHU CARE #Cancer #Autoimmunity and #Immunotherapy

@CareFhu
NewsImmuno's profile picture. The latest #Immunotherapy news from the best news sources, blogs, video channels and social media chat for the Immunotherapy community. Powered by Hanson Wade.

Immunotherapy News

@NewsImmuno
Immunotherapy_o's profile picture. Immunotherapy Open Access is a peer-reviewed journal focuses on topics such as Cancer immunotherapy, Tumor immunology,Chemotherapies and Adaptive immunity.

Immunotherapy Open Access

@Immunotherapy_o
immunophys's profile picture. Biopharmaceuticals Immunotherapy Orphan Drugs Rare Drugs

Immunotherapy

@immunophys
FH_IRC's profile picture. The Immunotherapy Integrated Research Center accelerates discovery by promoting cross-disciplinary and cross-divisional collaboration @fredhutch.

Immunotherapy IRC @fredhutch

@FH_IRC
JOFIonline's profile picture. JOI publishes lab studies and investigative clinical reports on immunomodulators, lymphokines, antibodies, and cell products in cancer biology and therapy.

J of Immunotherapy

@JOFIonline
CTI_ICR's profile picture. The CTI aims to increase communication between clinicians & scientists interested in translational immunotherapy @ICR_London and @royalmarsdenNHS.

Centre for Translational Immunotherapy (CTI)

@CTI_ICR
ImmunoTalks's profile picture. Listen to @ACIR_org brand new #podcast where we explore the latest findings in #cancer #immunotherapy.

Immunotherapy Talks, the podcast

@ImmunoTalks
Cancer_Immuno's profile picture. Acupressure, Massage, Energy, Hypnosis.

Michael Burke - Cancer Immunotherapy Coordinator.

@Cancer_Immuno
K_Yadavir's profile picture. MD Medicine, Medical oncologist
Karamvir Yadav
@K_Yadavir
Feb 7

New article alert from JCO: RAPIDO & PRODIGE-23 proved TNT works. NEOTERIC asks how to make TNT smarter. Signal-seeking today. Practice-changing tomorrow? #rectalcancer #immunotherapy #medtwitter #medscape @ASCO @JCO_ASCO @OncoAlert @OncBrothers @CancerNetwrk

K_Yadavir's tweet image. New article alert from JCO: RAPIDO & PRODIGE-23 proved TNT works. NEOTERIC asks how to make TNT smarter. Signal-seeking today. Practice-changing tomorrow? #rectalcancer #immunotherapy #medtwitter #medscape @ASCO @JCO_ASCO @OncoAlert @OncBrothers @CancerNetwrk
1
25
69
36
5K
ChandrakanthMv's profile picture. Medical Oncologist (Breast • GU • GI) Simplifying Oncology for DoctorsI Building MV Onco I Head Academics | Narayana Health Kolkata
MV Chandrakanth
@ChandrakanthMv
Mar 17

PD-L1 predicts in metastatic… but not early cancer. Why? • Metastatic → exhausted immunity • Needs PD-L1 removal • Early → strong immunity • Builds new response • Same shield, different outcome #MVOnco #Oncology #Immunotherapy

ChandrakanthMv's tweet image. PD-L1 predicts in metastatic… but not early cancer. Why? • Metastatic → exhausted immunity • Needs PD-L1 removal • Early → strong immunity • Builds new response • Same shield, different outcome #MVOnco #Oncology #Immunotherapy
1
14
52
18
2K
OscarTahuahua's profile picture. Medical oncologist @incanMX | Thoracic oncology | What’s changing in cancer care — and why it matters | @OncoAlert 🌎
Oscar Tahuahua
@OscarTahuahua
Mar 29

One hidden tumor population can decide if #immunotherapy works or fails In CRC A single clonal neoantigen → ~70% durable response vs ~10% without it dMMR tumors respond but still fail due to heterogeneity ICI clears immunogenic clones → low-immunogenic subclones survive,

OscarTahuahua's tweet image. One hidden tumor population can decide if #immunotherapy works or fails In CRC A single clonal neoantigen → ~70% durable response vs ~10% without it dMMR tumors respond but still fail due to heterogeneity ICI clears immunogenic clones → low-immunogenic subclones survive,
3
31
111
73
12K
ChandrakanthMv's profile picture. Medical Oncologist (Breast • GU • GI) Simplifying Oncology for DoctorsI Building MV Onco I Head Academics | Narayana Health Kolkata
MV Chandrakanth
@ChandrakanthMv
Mar 29

Phase 3 (PRESERVE-003): Gotistobart vs Docetaxel Post PD-(L)1 resistant sqNSCLC Early overlap → late separation (~6 months) HR 0.46 | Durable OS benefit 👉 Classic immunotherapy effect #MVOnco #NSCLC #Immunotherapy #LungCancer

ChandrakanthMv's tweet image. Phase 3 (PRESERVE-003): Gotistobart vs Docetaxel Post PD-(L)1 resistant sqNSCLC Early overlap → late separation (~6 months) HR 0.46 | Durable OS benefit 👉 Classic immunotherapy effect #MVOnco #NSCLC #Immunotherapy #LungCancer
3
7
33
14
3K
JAMA_current's profile picture. JAMA is an international peer-reviewed general medical journal published weekly online and in print, and a member of the @JAMANetwork family of journals.
JAMA
@JAMA_current
Mar 15

Allergy to peanuts affects approximately 2% of individuals in the US. 💡 This JAMA Insights discusses #PeanutAllergy, including diagnosis, introduction of peanuts to infant diet, and #immunotherapy options. ja.ma/4bnHMCf

JAMA_current's tweet image. Allergy to peanuts affects approximately 2% of individuals in the US. 💡 This JAMA Insights discusses #PeanutAllergy, including diagnosis, introduction of peanuts to infant diet, and #immunotherapy options. ja.ma/4bnHMCf
1
9
27
7
5K
myESMO's profile picture. The European Society for Medical Oncology (ESMO) is a reference organisation for cancer education and information, supporting the oncology community’s work.
ESMO - Eur. Oncology
@myESMO
Mar 13

#ESMORareCancers26: Adding first-line #immunotherapy to methotrexate improved response in patients with low-risk gestational trophoblastic neoplasia (#GTN) but must be balanced w/ safety & fertility considerations. ➡️Check out the #ESMODailyReporter: ow.ly/1gXW50YsKII

myESMO's tweet image. #ESMORareCancers26: Adding first-line #immunotherapy to methotrexate improved response in patients with low-risk gestational trophoblastic neoplasia (#GTN) but must be balanced w/ safety & fertility considerations. ➡️Check out the #ESMODailyReporter: ow.ly/1gXW50YsKII
0
5
10
2
1K
ChandrakanthMv's profile picture. Medical Oncologist (Breast • GU • GI) Simplifying Oncology for DoctorsI Building MV Onco I Head Academics | Narayana Health Kolkata
MV Chandrakanth
@ChandrakanthMv
Mar 31

“Clear cell ovarian cancer behaves differently. Not chemo-driven… but immune responsive. Phase 2 MoST-CIRCUIT shows Nivo+Ipi with 54% ORR and durable responses. Time to rethink biology. 🔥 #MVOnco #GynOnc #Immunotherapy”

ChandrakanthMv's tweet image. “Clear cell ovarian cancer behaves differently. Not chemo-driven… but immune responsive. Phase 2 MoST-CIRCUIT shows Nivo+Ipi with 54% ORR and durable responses. Time to rethink biology. 🔥 #MVOnco #GynOnc #Immunotherapy”
0
5
13
5
879
myESMO's profile picture. The European Society for Medical Oncology (ESMO) is a reference organisation for cancer education and information, supporting the oncology community’s work.
ESMO - Eur. Oncology
@myESMO
Mar 14

Some undifferentiated #sarcomas appear to be responsive to #immunotherapy but reliable #biomarkers are needed. @pawel_sobczuk explains more in his Opinion piece in the #ESMODailyReporter 📌 ow.ly/STcv50YtqLb #ESMORareCancers26

myESMO's tweet image. Some undifferentiated #sarcomas appear to be responsive to #immunotherapy but reliable #biomarkers are needed. @pawel_sobczuk explains more in his Opinion piece in the #ESMODailyReporter 📌 ow.ly/STcv50YtqLb #ESMORareCancers26
0
7
10
0
1K
myESMO's profile picture. The European Society for Medical Oncology (ESMO) is a reference organisation for cancer education and information, supporting the oncology community’s work.
ESMO - Eur. Oncology
@myESMO
Mar 28

📌@MdCurioni discusses the challenges of overcoming acquired resistance to #immunotherapy in #NSCLC, highlighting some positive and negative trial data from #ELCC26. Learn more in the #ESMODailyReporter: ow.ly/5vik50YA1aL

myESMO's tweet image. 📌@MdCurioni discusses the challenges of overcoming acquired resistance to #immunotherapy in #NSCLC, highlighting some positive and negative trial data from #ELCC26. Learn more in the #ESMODailyReporter: ow.ly/5vik50YA1aL
0
3
11
3
1K
DrBarbiOnc's profile picture. Gyn & Breast Onc. @NorthwellHealth Cancer Institute @CSHL. Leading the transition to molecular-first care. Enough thinking it’s time for knowing. Views mine.
Mali Barbi, MD MSc | Breast & Gyn Oncologist
@DrBarbiOnc
Apr 11

#Ovariancancer finally got its first OS benefit from #immunotherapy. #KEYNOTE_B96: #pembrolizumab plus weekly paclitaxel+/- Bev. HR 0.76 in CPS ≥1. HR 0.82 ITT. Lancet, tonight at #SGO2026. ** Two prior phase 3 ICI trials in this disease failed. Both targeted #PDL1.

DrBarbiOnc's tweet image. #Ovariancancer finally got its first OS benefit from #immunotherapy. #KEYNOTE_B96: #pembrolizumab plus weekly paclitaxel+/- Bev. HR 0.76 in CPS ≥1. HR 0.82 ITT. Lancet, tonight at #SGO2026. ** Two prior phase 3 ICI trials in this disease failed. Both targeted #PDL1.
0
2
14
2
782
OscarTahuahua's profile picture. Medical oncologist @incanMX | Thoracic oncology | What’s changing in cancer care — and why it matters | @OncoAlert 🌎
Oscar Tahuahua
@OscarTahuahua
Mar 15

We often use PD-L1 or CD8 density to predict response to #immunotherapy But this study suggests something else may matter more: DISTANCE In resectable NSCLC treated with neoadjuvant chemoimmunotherapy (multiplex spatial analysis, n=44), response was best predicted by how close

OscarTahuahua's tweet image. We often use PD-L1 or CD8 density to predict response to #immunotherapy But this study suggests something else may matter more: DISTANCE In resectable NSCLC treated with neoadjuvant chemoimmunotherapy (multiplex spatial analysis, n=44), response was best predicted by how close
2
18
71
46
6K
JCI_insight's profile picture. High-quality basic & translational research representative of biomedical specialties & physician-scientists. Bluesky: https://t.co/AksMLnEAMq
JCI insight
@JCI_insight
Feb 16

The morning advantage… Patrick G. Lyons @_plyons & team @washumedicine perform an observational study of 715 patients, reporting a connection between the time of day when CAR T-cell cancer #immunotherapy is administered and its effectiveness: doi.org/10.1172/jci.in…

JCI_insight's tweet image. The morning advantage… Patrick G. Lyons @_plyons & team @washumedicine perform an observational study of 715 patients, reporting a connection between the time of day when CAR T-cell cancer #immunotherapy is administered and its effectiveness: doi.org/10.1172/jci.in…
1
5
13
0
2K
pashtoonkasi's profile picture. Oncologist |Researcher| ColorectalCancer #CRCSM👨🏼‍🎓@MayoClinic @PittTweet Alum 🧬#ctDNA #LiquidBiopsies #PrecisionOncology @CityOfHope Views my own-COI @ASCO
Pashtoon Kasi MD, MS
@pashtoonkasi
Mar 31

Crossed 160 publications📝today. ✍🏽Building upon #immunotherapy💉, novel clinical trials, and #liquidBiopsies🩸 for patients with colorectal cancer and other malignancies. Latest article with⭐️@mariaf_teix 🔗: @OncoAlert sciencedirect.com/science/articl… @cityofhopeoc #CRCSM #cancer

pashtoonkasi's tweet image. Crossed 160 publications📝today. ✍🏽Building upon #immunotherapy💉, novel clinical trials, and #liquidBiopsies🩸 for patients with colorectal cancer and other malignancies. Latest article with⭐️@mariaf_teix 🔗: @OncoAlert sciencedirect.com/science/articl… @cityofhopeoc #CRCSM #cancer
pashtoonkasi's tweet image. Crossed 160 publications📝today. ✍🏽Building upon #immunotherapy💉, novel clinical trials, and #liquidBiopsies🩸 for patients with colorectal cancer and other malignancies. Latest article with⭐️@mariaf_teix 🔗: @OncoAlert sciencedirect.com/science/articl… @cityofhopeoc #CRCSM #cancer
6
9
42
5
4K
K_Yadavir's profile picture. MD Medicine, Medical oncologist
Karamvir Yadav
@K_Yadavir
Mar 31

Immunotherapy in gastric cancer — who really benefits? ✔️ MSI-H = best responses ✔️ PD-L1 helps (but not enough) ✔️ HER2+ → triplet therapy rising ❗ Most patients still don’t respond 🚀 Next step: smarter biomarkers + combinations #Oncology #CancerResearch #Immunotherapy

K_Yadavir's tweet image. Immunotherapy in gastric cancer — who really benefits? ✔️ MSI-H = best responses ✔️ PD-L1 helps (but not enough) ✔️ HER2+ → triplet therapy rising ❗ Most patients still don’t respond 🚀 Next step: smarter biomarkers + combinations #Oncology #CancerResearch #Immunotherapy
2
9
28
7
1K
PatrickHwuMD's profile picture. Moffitt Cancer Center President and CEO, @MoffittNews. Tumor immunologist. Inspired leader. Girl dad. #DocsWhoRock. Driven to save more lives from #cancer.
Dr. Patrick Hwu
@PatrickHwuMD
Apr 11

🧬 #ScienceSaturday ❓ What if we could block cancer’s ability to survive in low-oxygen environments and make #immunotherapy more effective? ➡️ In a new study published in the Journal of Experimental Medicine (@JExpMed), researchers developed dual inhibitors targeting HIF-1 and

PatrickHwuMD's tweet image. 🧬 #ScienceSaturday ❓ What if we could block cancer’s ability to survive in low-oxygen environments and make #immunotherapy more effective? ➡️ In a new study published in the Journal of Experimental Medicine (@JExpMed), researchers developed dual inhibitors targeting HIF-1 and
3
20
69
23
5K
Tsinghua_Uni's profile picture. Tsinghua University is a research university located in Beijing, China, established in 1911.
Tsinghua University
@Tsinghua_Uni
Jan 13

Congrats to Prof. Yang-xin Fu from @MedTsinghua on being named a 2025 @Clarivate Highly Cited Researcher for the seventh consecutive year! 🎉 A pioneer in cancer #immunotherapy, he continues to fuel breakthroughs in developing antibody-cytokine fusion protein or vaccine.

Tsinghua_Uni's tweet image. Congrats to Prof. Yang-xin Fu from @MedTsinghua on being named a 2025 @Clarivate Highly Cited Researcher for the seventh consecutive year! 🎉 A pioneer in cancer #immunotherapy, he continues to fuel breakthroughs in developing antibody-cytokine fusion protein or vaccine.
1
8
26
0
1K
IASLC's profile picture. The International Association for the Study of Lung Cancer is the only global organization dedicated solely to the study of lung cancer. #LCSM
IASLC
@IASLC
Apr 2

#HT26 Abstract submission closing soon! Share your research at #IASLC HT26 and join global experts exploring resistance to #immunotherapy. 🇮🇪 Dublin, Ireland 🗓️June 26–27 📝Deadline: April 15 bit.ly/3NbSROT #LungCancer #Oncology #Research

IASLC's tweet image. #HT26 Abstract submission closing soon! Share your research at #IASLC HT26 and join global experts exploring resistance to #immunotherapy. 🇮🇪 Dublin, Ireland 🗓️June 26–27 📝Deadline: April 15 bit.ly/3NbSROT #LungCancer #Oncology #Research
0
4
7
0
756
myESMO's profile picture. The European Society for Medical Oncology (ESMO) is a reference organisation for cancer education and information, supporting the oncology community’s work.
ESMO - Eur. Oncology
@myESMO
Apr 8

#ESMORareCancers26: ARCAGEN highlights a gap between molecular profiling and treatment in advanced #RareCancers. Among patients with clinically actionable alterations, only 15% received matched targeted therapy or #immunotherapy. #ESMODailyReporter 📌 ow.ly/yk5150YFAXT

myESMO's tweet image. #ESMORareCancers26: ARCAGEN highlights a gap between molecular profiling and treatment in advanced #RareCancers. Among patients with clinically actionable alterations, only 15% received matched targeted therapy or #immunotherapy. #ESMODailyReporter 📌 ow.ly/yk5150YFAXT
0
2
7
1
1K
Dr_ElvinaA's profile picture. Assoc. Prof. | Medical Oncologist | ESO Ambassador Fighting for hope, seeking truth, raising sons, crossing borders — reminding the world: life matters.
Elvina Almuradova
 @Dr_ElvinaA
Mar 25

Immunotherapy is not just tumor biology. Thymic health predicts outcomes: • PFS HR 0.65 • OS HR 0.56 • Independent of PD-L1 & TMB • Even in PD-L1 <1% → ↓ progression ~44% We may be treating the tumor… But the response depends on the patient’s immune age. #Immunotherapy

Dr_ElvinaA's tweet image. Immunotherapy is not just tumor biology. Thymic health predicts outcomes: • PFS HR 0.65 • OS HR 0.56 • Independent of PD-L1 &amp;amp; TMB • Even in PD-L1 &amp;lt;1% → ↓ progression ~44% We may be treating the tumor… But the response depends on the patient’s immune age. #Immunotherapy
1
7
17
4
1K
myESMO's profile picture. The European Society for Medical Oncology (ESMO) is a reference organisation for cancer education and information, supporting the oncology community’s work.
ESMO - Eur. Oncology
@myESMO
Mar 27

#ELCC26: Non-inferiority for overall survival was demonstrated with late versus early IV #immunotherapy administration in the ETOP-Roche i-TiMES meta-analysis of 8 trials in ##LungCancer. Read more in the #ESMODailyReporter 📌ow.ly/LYNw50YzJ72

myESMO's tweet image. #ELCC26: Non-inferiority for overall survival was demonstrated with late versus early IV #immunotherapy administration in the ETOP-Roche i-TiMES meta-analysis of 8 trials in ##LungCancer. Read more in the #ESMODailyReporter 📌ow.ly/LYNw50YzJ72
0
7
13
2
1K

Something went wrong.


Something went wrong.


United States Trends